- Home
- QNRX
as 12-18-2024 1:41pm EST
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | KFAR SABA |
| Market Cap: | 3.0M | IPO Year: | N/A |
| Target Price: | $4.00 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.48 - $6.18 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Quoin Pharmaceuticals Ltd. News
QNRX Breaking Stock News: Dive into QNRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 hours ago
Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
Argus Research
15 days ago
Daily – Vickers Top Insider Picks for 12/03/2024
Argus Research
16 days ago
Daily – Vickers Top Insider Picks for 12/02/2024
Argus Research
19 days ago
Daily – Vickers Top Insider Picks for 11/29/2024
Argus Research
21 days ago
Daily – Vickers Top Insider Picks for 11/27/2024
Argus Research
22 days ago
Daily – Vickers Top Insider Picks for 11/26/2024
Argus Research
23 days ago
Daily – Vickers Top Insider Picks for 11/25/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 11/22/2024
Compare QNRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QNRX Quoin Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.